Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BRG01 in EBV-positive Nasopharyngeal Carcinoma
NCT05864924Phase 1Completed
- Sponsor
- Biosyngen
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Allogeneic CAR-T, HLA-matched TCR-T, HLA-independent TCR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous anti-EBV CAR T cells BRG01 in nasopharyngeal carcinoma (NPC) (3 cohorts), sponsored by Biosyngen. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started May 2023; status: completed.
02
Drugs
autologous anti-EBV CAR T cells BRG01
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05864924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864924.